Evidence map›Paper›PMID 29427040›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2018

Novel epigenetic markers for gastric cancer risk stratification in individuals after Helicobacter pylori eradication.

Masahiro Maeda, Satoshi Yamashita, Taichi Shimazu, Naoko Iida, Hideyuki Takeshima, Takeshi Nakajima, Ichiro Oda, Sohachi Nanjo, Chika Kusano, Akiko Mori and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. World Endoscopy Organization Position Statements for Artificial Intelligence in Endoscopic Diagnosis of Gastric Epithelial Neoplasia.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026
    Review
  5. Review
  6. Concurrent hypermethylation of CpG islands and hypomethylation of CpG-poor regions are associated with gastric cancer risk after Helicobacter pylori eradication.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  7. Article
  8. Article
  9. Epigenetic alterations inJournal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025
    Review
  10. Gut and liver · 2023
    Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Role of ELMO1 in inflammation and cancer-clinical implications.Cellular oncology (Dordrecht, Netherlands) · 2022
    Review
  16. Changes in Gastric Mucosal Glycosylation Before and After Helicobacter pylori Eradication Using Lectin Microarray Analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Masahiro MaedaDivision of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan. tushijim@ncc.go.jp.
Satoshi YamashitaDivision of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
Taichi ShimazuEpidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Naoko IidaDivision of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
Hideyuki TakeshimaDivision of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
Takeshi NakajimaEndoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Ichiro OdaEndoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Sohachi NanjoThird Department of Internal Medicine, University of Toyama, Toyama, Japan.
Chika KusanoDivision of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Akiko MoriDivision of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
Hiroshi MoroDivision of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
Harumi YamadaDivision of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.
Shoichiro TsuganeEpidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Toshiro SugiyamaThird Department of Internal Medicine, University of Toyama, Toyama, Japan.
Yoshiharu SakaiDepartment of Gastrointestinal Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Toshikazu UshijimaDivision of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan.

Funding

Japan Agency for Medical Research and Development 15ck0106023h0002Japan Agency for Medical Research and Development 16ck0106023h0003Japan Agency for Medical Research and Development 17ck0106267h0001
6 · The paper itself

Abstract

backgroundThe risk stratification of healthy individuals after Helicobacter pylori eradication is an urgent issue. The assessment of aberrant DNA methylation accumulated in gastric tissues with normal appearance, which can reflect overall epigenomic damage, is a promising strategy. We aimed to establish novel epigenetic cancer risk markers for H. pylori-eradicated individuals.

methodsGastric mucosa was collected from eight healthy volunteers without H. pylori infection (G1), 75 healthy individuals with gastric atrophy (G2), and 94 gastric cancer patients (G3) after H. pylori eradication. Genome-wide analysis was conducted using Infinium 450 K and differentially methylated probes were screened using large difference and iEVORA-based methods. Bisulfite pyrosequencing was used for validation.

resultsScreening, using 8 G1, 12 G2, and 12 G3 samples, isolated 57 candidates unmethylated in G1 and differentially methylated in G3 compared with G2. Validation for nine candidate markers (FLT3, LINC00643, RPRM, JAM2, ELMO1, BHLHE22, RIMS1, GUSBP5, and ZNF3) in 63 G2 and 82 G3 samples showed that all of them had significantly higher methylation levels in G3 than in G2 (P < 0.0001). Their methylation levels were highly correlated, which indicated that they reflect overall epigenomic damage. The candidates had sufficient performance (AUC: 0.70-0. 80) and high odds ratios (5.43-23.41), some of which were superior to a previous marker, miR-124a-3. The methylation levels of our novel markers were not associated with gastric atrophy, gender, or age.

conclusionsNovel epigenetic markers for gastric cancer risk optimized for H. pylori-eradicated individuals were established.

Indexed as

Epigenesis, GeneticAdultAgedAge FactorsAtrophyBiomarkers, TumorDNA MethylationFemaleGastric MucosaGene Expression Regulation, NeoplasticGenome-Wide Association StudyHelicobacter InfectionsHelicobacter pyloriHumansMaleReproducibility of ResultsBiomarkers, TumorCancer risk markerDNA methylationEpigeneticsGastric cancerHelicobacter pylori

Identifiers

PMID29427040

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.